pramlintide

(redirected from Symlin)
Also found in: Medical.

pram·lin·tide

 (prăm′lĭn-tīd′)
n.
An injectable drug that is a synthetic analog of the hormone amylin, used in the form of its acetate salt to treat type 1 and type 2 diabetes.

[pram-, of unknown origin + -lintide, amylin derivative or mimic suffix ((amy)lin + (pep)tide).]
Translations

pramlintide

n pramlintida
References in periodicals archive ?
Amitriptyline* Elavil Bupropion * Wellbutrin, Zyban Clomipramine* Anafranil Desipramine* Norpramin Exenatide* Byetta, Bydureon Imipramine* Tofranil Levomilnacipran * Fetzima Liraglutide * Victoza, Saxenda Lorcaserin * Belviq Metformin * Glucophage Methylphenidate * Ritalin, Methylin Mirtazapine* Remeron Naltrexone/bupropion * Contrave Nefazodone * Serzone Nortriptyline* Pamelor Olanzapine* Zyprexa Orlistat* Xenical Paroxetine * Paxil Phentermine/topiramate * Qsymia Pramlintide* Symlin Protriptyline* Vivactil Quetiapine* Seroquel Trazodone * Desyrel, Oleptro Vilazodone* Viibryd Vortioxetine * Trintellix Zonisamide * Zonegran
suspension), Myalept (metreleptin) and Symlin (pramlintide acetate).
With the acquisition, AstraZeneca possess the intellectual property and global rights for the development, manufacture, and commercialization of BMS diabetes business, which comprises Onglyza (saxagliptin), Kombiglyze XR (saxagliptin and metformin HCl extended release), Komboglyze (saxagliptin and metformin HCl), dapagliflozin (marketed as Forxiga outside the US and Farxiga in the US), Xigduo (dapagliflozin and metformin HCl), Byetta (exenatide), Bydureon (exenatide extended-release for injectable suspension), metreleptin, and Symlin (pramlintide acetate).
The acquisition offers AstraZeneca ownership of the intellectual property and global rights for the development, manufacture and commercialisation of the diabetes business, including Onglyza, Kombiglyze XR, Komboglyze, dapagliflozin, Xigduo, Byetta, Bydureon, metreleptin and Symlin.
In March 2005, for example, the RiskMAP that accompanied the FDA's approval of a diabetes drug called Symlin prohibited the company from conducting any direct-to-consumer advertising or journal advertising for one year following approval, and also restricted promotion primarily to physicians who specialize in diabetes management and who are supported by certified diabetes educators.
The morning after the company's diabetes drug, Symlin, was finally approved by the federal government after 18 years of research and development, she arrived in the office in a Sleeping Beauty costume and handed out copies of the fairy tale.
In July 2012, BMS and AZ worked together to acquire Amylin and its injectable diabetes treatments, Byetta, By-dureon and Symlin, for $5.
This agreement will see the company sell its global diabetes business that was part of its collaboration with AstraZeneca, which includes Onglyza (saxagliptin), Kombiglyze XR/Komboglyze (saxagliptin and metformin HCl extended release), dapagliflozin (marketed as Forxiga outside the US), Byetta (exenatide), Bydureon (exenatide extended release for injectable suspension), Symlin (pramlintide acetate) and metreleptin.
Upon completion of the transaction, AstraZeneca will own intellectual property and global rights for the development, manufacture and commercialisation of the diabetes business, which includes Onglyza (saxagliptin), Kombiglyze XR (saxagliptin and metformin HCl extended release), Komboglyze (saxagliptin and metformin HCl), dapagliflozin (marketed as Forxiga outside the US), Byetta (exenatide), Bydureon (exenatide extended-release for injectable suspension), metreleptin and Symlin (pramlintide acetate).
Sales of Byetta edged higher and Symlin revenue slipped, but a change in accounting cut its revenue by $27.